Progenics Outlicenses Japanese Rights to Relistor®
By Helen Scrutton
Pharma Deals Review: Vol 2008 Issue 101 (Table of Contents)
Published: 16 Oct-2008
DOI: 10.3833/pdr.v2008.i101.116 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Ono Pharmaceutical is to develop Relistor® (methylnaltrexone bromide) for the Japanese market, following a licensing deal with Progenics Pharmaceuticals...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS